- Wang, Lushun;
- Bohmer, Monica;
- Wang, Jinhua;
- Nardella, Flore;
- Calla, Jaeson;
- Laureano De Souza, Mariana;
- Schindler, Kyra;
- Montejo, Lukas;
- Mittal, Nimisha;
- Rocamora, Frances;
- Treat, Mayland;
- Charlton, Jordan;
- Tumwebaze, Patrick;
- Rosenthal, Philip;
- Cooper, Roland;
- Chakrabarti, Ratna;
- Winzeler, Elizabeth;
- Chakrabarti, Debopam;
- Gray, Nathanael
While progress has been made in the effort to eradicate malaria, the disease remains a significant threat to global health. Acquired resistance to frontline treatments is emerging in Africa, urging a need for the development of novel antimalarial agents. Repurposing human kinase inhibitors provides a potential expedited route given the availability of a diverse array of kinase-targeting drugs that are approved or in clinical trials. Phenotypic screening of a library of type II human kinase inhibitors identified compound 1 as a lead antimalarial, which was initially developed to target human ephrin type A receptor 2 (EphA2). Here, we report a structure-activity relationship study and lead optimization of compound 1, which led to compound 33, with improved antimalarial activity and selectivity.